Tag: AHA 2016
AHA 2016: Mortality rate with FFR-guided treatment of multivessel disease is unexpectedly high
The results of the FUTURE (Functional testing underlying revascularisation) trial indicate that ...
AHA 2016: Heparin plus tirofiban is safe and effective for use during PCI
A new study, by researchers from the Intermountain Medical Center Heart Institute (Salt Lake Cit...
AHA 2016: Low-dose rivaroxaban reduces clinically significant bleeding in PCI patients with atrial fibrillation
Two drug regimens involving low doses of rivaroxaban (Xarelto, Bayer)—one with a 15mg once daily...
AHA 2016: Elizabeth M McNally wins AHA prize for research into genetic flaws responsible for inherited human disorders including heart failure
The American Heart Association (AHA) awarded its Basic Research Prize for 2016 to Elizabeth M Mc...
AHA 2016: MOMENTUM 3 shows HeartMate 3 LVAD improves clinical outcomes compared with HeartMate II LVAD
The results of the MOMENTUM 3 US IDE clinical study, which were presented at a late-breaking cli...
AHA 2016: Strong positive one-year data for Corvia Medical’s InterAtrial shunt device
Corvia Medical has announced one-year follow-up data from the REDUCE LAP-HF clinical study of its In...
AHA 2016: Incomplete revascularisation after PCI increases risk of adverse events after surgery
Ehrin J Armstrong (Section of Cardiology, Denver VA Medical Center and University of Colorado Sc...
AHA 2016: Two thirds of patients experience plaque regression with the PCSK9 inhibitor evolocumab
Amgen has announced that adding its PCSK9 inhibitor evolocumab (Repatha) to optimised statin the...
